Serology response rates and anti-S levels
Patient cohorts . | Serology response rate . | Anti-S levels (AU/mL) for responding patients . | ||
|---|---|---|---|---|
| Initial vaccination (n = 202) n (%) . | Booster vaccination (n = 114) n (%) . | Initial vaccination (n = 202) Median (range) . | Booster vaccination (n = 114) Median (range) . | |
| Overall | 114 (56) | 78 (66) | 202.1 (1.1->25 000) | 5350 (0.9->25 000) |
| Time between vaccination and first serologic assessment | (95% CI, 50-63) Median: 59 days (range, 8-124) | (95% CI, 60-77) Median: 40 days (range, 7-128) | ||
| No treatment | 82 (70) | 50 (79) | 303 (1.1->25 000) | 10327 (1.2->25 000) |
| Treatment naïve | 56 (79) | 34 (77) | 238 (1.1->25 000) | 9625 (2.4->25 000) |
| BTK inhibitor | 18 (44) OR, 0.34 (0.17-0.71) | 19 (66) OR, 0.49 (0.19-1.32) | 16.4 (1.3-1474) | 365.9 (1.6-> 25 000) |
| Venetoclax | 2 (40) OR, 0.29 (0.05-1.83) | 1 (50) OR, 0.26 (0.02-4.44) | 83 (64.5-101) | 795 -- |
| Venetoclax + CD20 Mab | 4 (31) OR 0.20 (0.06-0.68) | 3 (43) OR, 0.02 (0.04-0.98) | 750 (4.6-2481) | 1.35 (0.9-5237) |
| BTK inhibitor + CD20 Mab | 1 (14) OR, 0.07 (0.01-0.63) | 1 (20) OR, 0.07 (0.01-0.63) | 87.7 | 146 -- |
| BTK inhibitor + venetoclax | 3 (38) OR, 0.26 (0.06-1.16) | 2 (50) OR, 0.26 (0.03-2.03) | 32 (1.4-390) | 1094 (51-2137) |
| BTK inhibitor + venetoclax + CD20 Mab | 0 (0) -- | 1 (33) OR, 0.13 (0.01-1.55) | N/A | 530 -- |
| Other | 4 (50) | 1 (100) | 2162 (2.7-7980) | 2660 -- |
| Mo since CD20 Mab | ||||
| On treatment – 6 mo | 7 (26) | 5 (42) | 87.7 (1.5-2481) | 530 (0.9-5237) |
| 7-12 mo | 4 (40) | 2 (33) | 274 (4.6-972.5) | 33 (8.5-57.6) |
| >12 mo | 28 (51) | 22 (73) | 246 (1.4-11 882) | 2971 (1.2->25 000) |
| No exposure | 75 (68) | 49 (74) | 57 (1.1->25 000) | 5463 (1.6->25 000) |
Patient cohorts . | Serology response rate . | Anti-S levels (AU/mL) for responding patients . | ||
|---|---|---|---|---|
| Initial vaccination (n = 202) n (%) . | Booster vaccination (n = 114) n (%) . | Initial vaccination (n = 202) Median (range) . | Booster vaccination (n = 114) Median (range) . | |
| Overall | 114 (56) | 78 (66) | 202.1 (1.1->25 000) | 5350 (0.9->25 000) |
| Time between vaccination and first serologic assessment | (95% CI, 50-63) Median: 59 days (range, 8-124) | (95% CI, 60-77) Median: 40 days (range, 7-128) | ||
| No treatment | 82 (70) | 50 (79) | 303 (1.1->25 000) | 10327 (1.2->25 000) |
| Treatment naïve | 56 (79) | 34 (77) | 238 (1.1->25 000) | 9625 (2.4->25 000) |
| BTK inhibitor | 18 (44) OR, 0.34 (0.17-0.71) | 19 (66) OR, 0.49 (0.19-1.32) | 16.4 (1.3-1474) | 365.9 (1.6-> 25 000) |
| Venetoclax | 2 (40) OR, 0.29 (0.05-1.83) | 1 (50) OR, 0.26 (0.02-4.44) | 83 (64.5-101) | 795 -- |
| Venetoclax + CD20 Mab | 4 (31) OR 0.20 (0.06-0.68) | 3 (43) OR, 0.02 (0.04-0.98) | 750 (4.6-2481) | 1.35 (0.9-5237) |
| BTK inhibitor + CD20 Mab | 1 (14) OR, 0.07 (0.01-0.63) | 1 (20) OR, 0.07 (0.01-0.63) | 87.7 | 146 -- |
| BTK inhibitor + venetoclax | 3 (38) OR, 0.26 (0.06-1.16) | 2 (50) OR, 0.26 (0.03-2.03) | 32 (1.4-390) | 1094 (51-2137) |
| BTK inhibitor + venetoclax + CD20 Mab | 0 (0) -- | 1 (33) OR, 0.13 (0.01-1.55) | N/A | 530 -- |
| Other | 4 (50) | 1 (100) | 2162 (2.7-7980) | 2660 -- |
| Mo since CD20 Mab | ||||
| On treatment – 6 mo | 7 (26) | 5 (42) | 87.7 (1.5-2481) | 530 (0.9-5237) |
| 7-12 mo | 4 (40) | 2 (33) | 274 (4.6-972.5) | 33 (8.5-57.6) |
| >12 mo | 28 (51) | 22 (73) | 246 (1.4-11 882) | 2971 (1.2->25 000) |
| No exposure | 75 (68) | 49 (74) | 57 (1.1->25 000) | 5463 (1.6->25 000) |